Concepedia

Kelly L. Flanagan

KL

4

Publications

125

Citations

4

H-Index

1993

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Kelly L. Flanagan is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicinal chemistry, pharmacotherapy, and drug discovery.

Top concepts

Publications per year

1993–1994

4

Publications

4

Triazolinone Biphenylsulfonamides as Angiotensin II Receptor Antagonists with High Affinity for Both the AT1 and AT2 Subtypes

Linda Chang, Wallace T. Ashton, Kelly L. Flanagan et al. · Journal of Medicinal Chemistry · 1994 · 49 citations · Full text

Triazolinone Biphenylsulfonamide Derivatives as Orally Active Angiotensin II Antagonists with Potent AT1 Receptor Affinity and Enhanced AT2 Affinity

Wallace T. Ashton, Linda Chang, Kelly L. Flanagan et al. · Journal of Medicinal Chemistry · 1994 · 37 citations · Full text

Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones

Linda Chang, Wallace T. Ashton, Kelly L. Flanagan et al. · Journal of Medicinal Chemistry · 1993 · 28 citations · Full text

, , +14

Triazolinones as nonpeptide angiotensin II antagonists. 2. discovery of a potent and orally active triazolinone acylsulfonamide

Linda Chang, Wallace T. Ashton, Kelly L. Flanagan et al. · Bioorganic & Medicinal Chemistry Letters · 1994 · 11 citations

, , +8

Rows per page

1–4 of 4